




# Stock Selection Guide

Company	Bio-Reference Labs	Price Date	09/16/13
Study by	W. Nixon	Data Date	09/11/13
Sector	Healthcare	Data Source	BI
Industry	Diagnostics & Research	Reference	Morningsta
Preferred(\$M)	0.0		
Common(M Shares)	27.7	% Insiders	13.5
Debt(\$M)	34.6	% Institutions	97.3
% Debt to Tot.Cap.	13.2	Quality	

## 1 Growth Analysis

NAS: BRLI



(1) Historical Sales Growth	22.4 %	(3) Historical Earnings Per Share Growth	22.3 %	www.iclub.com
(2) Estimated Future Sales Growth	8.0 %	(4) Estimated Future Earnings Per Share Growth	8.0 %	
(5) Sales Growth R <sup>2</sup>	1.00	(6) Earnings Per Share Growth R <sup>2</sup>	0.97	

## 2 QUALITY ANALYSIS

Company **Bio-Reference Labs** (BRLI)

09/16/13

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	5 YEAR AVG.	TREND UP / DOWN
<b>A</b> % Pre-tax Profit on Sales	7.9	8.9	7.0	8.7	9.1	8.9	10.6	10.3	11.6	11.3	10.5	UP
<b>B</b> % ROE (Beginning Yr)	<del>7.9</del>	25.6	18.0	21.3	19.2	18.0	21.3	20.9	23.6	22.2	21.2	UP
<b>C</b> % Debt to Equity	7.1	10.7	7.8	10.3	10.9	8.6	6.7	5.0	5.8	6.0	6.4	EVEN

## 3 PRICE, PRICE/EARNINGS RATIO and DIVIDEND ANALYSIS

CURRENT PRICE (P/E) 29.36 (17.2) 52-WEEK HIGH (P/E) 32.86 (19.2) 52-WEEK LOW (P/E) 23.36 (13.7)

Fiscal Year	High Price	Low Price	EPS	High P/E	Low P/E	Dividend	% Payout	% High Yield
1 2008	17.9	10.0	0.56	32.0	17.9	0.000	0.0	0.0
2 2009	18.1	9.2	0.79	23.1	11.7	0.000	0.0	0.0
3 2010	24.7	15.4	0.94	26.3	16.4	0.000	0.0	0.0
4 2011	26.0	16.7	1.29	20.2	12.9	0.000	0.0	0.0
5 2012	32.9	11.4	1.51	21.8	7.5	0.000	0.0	0.0
6 AVERAGE		12.5		24.7	13.3		0.0	
AVERAGE P/E RATIO		19.0	PROJECTED P/E RATIO		15.9	TTM EPS		1.71
CURRENT P/E RATIO		17.2	PEG RATIO		2.0	FTM EPS		1.85
RELATIVE VALUE		90.5	PROJ. RELATIVE VALUE		83.7	AVG TTM + FTM EPS		1.78

## 4 EVALUATING REWARD and RISK over the next 5 years

### A FUTURE HIGH PRICE ANALYSIS -- NEXT 5 YEARS

Selected High P/E 24.7 X Estimated High Earnings/Share 2.22 = Forecast High Price \$ 54.8

### B FUTURE LOW PRICE ANALYSIS -- NEXT 5 YEARS

(a) Sel. Low P/E 13.3 X Estimated Low Earnings/Share 1.51 = \$ 20.1  
(as adj.)

(b) Average 5-Year Low Price = 12.5

(c) Recent Severe Low Price = 11.4

(d) Price Dividend Will Support = Present Divd. ÷ High Yield = 0.000 ÷ 0.000 = 0.0

Selected Estimated Low Price = \$ 20.1

### C PRICE RANGES

Forecast High Price 54.8 - Estimated Low Price 20.1 = Range 34.7 25% of Range = 8.7

BUY (Lower 25% of Range) = 20.1 to 28.8

MAYBE (Middle 50% of Range) = 28.8 to 46.1

SELL (Upper 25% of Range) = 46.1 to 54.8

Current Price 29.360 is in the Hold Range

### D UPSIDE/DOWNSIDE ANALYSIS (Potential Gain vs. Risk of Loss)

(Forecast High Price 54.8 - Current Price 29.360) ÷ (Current Price 29.360 - Estimated Low Price 20.1) = 2.7 To 1

## 5 TOTAL RETURN ANALYSIS

### A CURRENT YIELD

Present Full Year's Dividend \$ 0.000 ÷ Current Price of Stock \$ 29.360 = 0.0 % Present Yield or % Returned on Purchase Price

### B AVERAGE YIELD - USING FORECAST HIGH P/E

Avg. % Payout 0.0 ÷ Forecast High P/E 24.7 = Avg. Yield 0.0

### AVERAGE YIELD - USING FORECAST AVERAGE P/E

Avg. % Payout 0.0 ÷ Forecast Avg P/E 19.0 = Avg. Yield 0.0

### C % COMPOUND ANNUAL TOTAL RETURN - USING FORECAST HIGH P/E

Average Yield 0.0 % + Annual Appreciation 13.3 % = Compound Annual Total Return 13.3 %

### D % PROJECTED AVERAGE RETURN - USING FORECAST AVERAGE P/E

Average Yield 0.0 % + Annual Appreciation 7.5 % = Projected Average Total Return 7.5 %

# PERT-A Graph

Company Bio-Reference Labs (BRLI)

